These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 1705062)

  • 21. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
    Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
    Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preoperative staging of pelvic lymph nodes in prostate cancer by 11C-choline PET.
    de Jong IJ; Pruim J; Elsinga PH; Vaalburg W; Mensink HJ
    J Nucl Med; 2003 Mar; 44(3):331-5. PubMed ID: 12620996
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predicting the patient at low risk for lymph node metastasis with localized prostate cancer: an analysis of four statistical models.
    Spevack L; Killion LT; West JC; Rooker GM; Brewer EA; Cuddy PG
    Int J Radiat Oncol Biol Phys; 1996 Feb; 34(3):543-7. PubMed ID: 8621276
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predicting pelvic lymph node involvement in current-era prostate cancer.
    Rahman S; Cosmatos H; Dave G; Williams S; Tome M
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):906-10. PubMed ID: 21300478
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The extent of lymphadenectomy for pTXNO prostate cancer does not affect prostate cancer outcome in the prostate specific antigen era.
    DiMarco DS; Zincke H; Sebo TJ; Slezak J; Bergstralh EJ; Blute ML
    J Urol; 2005 Apr; 173(4):1121-5. PubMed ID: 15758719
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer.
    Cagiannos I; Karakiewicz P; Eastham JA; Ohori M; Rabbani F; Gerigk C; Reuter V; Graefen M; Hammerer PG; Erbersdobler A; Huland H; Kupelian P; Klein E; Quinn DI; Henshall SM; Grygiel JJ; Sutherland RL; Stricker PD; Morash CG; Scardino PT; Kattan MW
    J Urol; 2003 Nov; 170(5):1798-803. PubMed ID: 14532779
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Robotic extended pelvic lymphadenectomy for intermediate- and high-risk prostate cancer.
    Yuh BE; Ruel NH; Mejia R; Wilson CM; Wilson TG
    Eur Urol; 2012 May; 61(5):1004-10. PubMed ID: 22366188
    [TBL] [Abstract][Full Text] [Related]  

  • 28. External validation of the updated nomogram predicting lymph node invasion in patients with prostate cancer undergoing extended pelvic lymph node dissection.
    Gacci M; Schiavina R; Lanciotti M; Masieri L; Serni S; Vagnoni V; Abdollah F; Carini M; Martorana G; Montorsi F
    Urol Int; 2013; 90(3):277-82. PubMed ID: 23296120
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Correlation of clinical stage, serum prostatic acid phosphatase and preoperative Gleason grade with final pathological stage in 275 patients with clinically localized adenocarcinoma of the prostate.
    Oesterling JE; Brendler CB; Epstein JI; Kimball AW; Walsh PC
    J Urol; 1987 Jul; 138(1):92-8. PubMed ID: 3599229
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Preoperative prediction of the presence of lymph node metastasis of prostatic carcinoma: reliability and clinical significance].
    Trinchieri A; Nespoli R; Rovera F
    Arch Ital Urol Androl; 1995 Jun; 67(3):203-5. PubMed ID: 7544667
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prostate specific antigen in patients with clinical stage C prostate cancer: relation to lymph node status and grade.
    Greskovich FJ; Johnson DE; Tenney DM; Stephenson RA
    J Urol; 1991 Apr; 145(4):798-801. PubMed ID: 1706439
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Correlation between the preoperative serum prostate specific antigen, Gleason score, and clinical staging with pathological outcome following robot-assisted radical prostatectomy: an Indian experience.
    Singh P; Dogra PN; Gupta NP; Nayyar R; Seth A; Javali TD; Kumar R
    Indian J Cancer; 2011; 48(4):483-7. PubMed ID: 22293265
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Sentinel lymph node dissection in prostate cancer. Experience after more than 800 interventions].
    Weckermann D; Hamm M; Dorn R; Wagner T; Wawroschek F; Harzmann R
    Urologe A; 2006 Jun; 45(6):723-7. PubMed ID: 16586052
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Updated nomogram predicting lymph node invasion in patients with prostate cancer undergoing extended pelvic lymph node dissection: the essential importance of percentage of positive cores.
    Briganti A; Larcher A; Abdollah F; Capitanio U; Gallina A; Suardi N; Bianchi M; Sun M; Freschi M; Salonia A; Karakiewicz PI; Rigatti P; Montorsi F
    Eur Urol; 2012 Mar; 61(3):480-7. PubMed ID: 22078338
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relationship between grade and stage of adenocarcinoma of the prostate and regional pelvic lymph node metastases.
    Zincke H; Farrow GM; Myers RP; Benson RC; Furlow WL; Utz DC
    J Urol; 1982 Sep; 128(3):498-501. PubMed ID: 7120555
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Value of PSA and (pre- postoperative) Gleason in predicting the potential lymphatic involvement in patients with prostatic cancer].
    Gómez Veiga F; Díaz Bermúdez J; Alvarez Castelo L; Lorenzo Patiño MJ; Rodríguez Rivera J; Chantada Abal V; Vázquez Martul E; González Martín M
    Arch Esp Urol; 1997; 50(1):33-9. PubMed ID: 9182486
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Extent of pelvic lymph node dissection and the impact of standard template dissection on nomogram prediction of lymph node involvement.
    Godoy G; Chong KT; Cronin A; Vickers A; Laudone V; Touijer K; Guillonneau B; Eastham JA; Scardino PT; Coleman JA
    Eur Urol; 2011 Aug; 60(2):195-201. PubMed ID: 21257258
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Usefulness of prostate-specific antigen in the diagnosis of lymphatic metastases in cancer of the prostate].
    Saad F; Bertrand P; Paquin JM; Péloquin F
    Ann Chir; 1995; 49(8):680-4. PubMed ID: 8561420
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Significance of staging pelvic lymphadenectomy for prostatic cancer.
    Fujioka T; Koike H; Aoki H; Ohhori T; Chiba R; Okamoto S
    Urol Int; 1987; 42(5):380-4. PubMed ID: 3433586
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Histopathological characteristics of lymph node metastases predict cancer-specific survival in node-positive prostate cancer.
    Boormans JL; Wildhagen MF; Bangma CH; Verhagen PC; van Leenders GJ
    BJU Int; 2008 Dec; 102(11):1589-93. PubMed ID: 18710447
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.